Economic Reform Essential to Revitalize Antibiotic Innovation

Antimicrobial resistance (AMR) poses a growing global threat, yet the pipeline for new antibiotics is dwindling due to a flawed economic model. Developing these drugs is costly and time-consuming, while low prices and restricted usage as last-resort treatments prevent companies from recouping investments. This article argues that governments must implement both push and pull incentives to sustain innovation. Push incentives, such as funding from CARB-X and BARDA, reduce early-stage research costs. More critically, pull incentives like the UK’s subscription-based Netflix model guarantee revenue regardless of sales volume, ensuring market viability. Analysis suggests G7 and EU nations should collectively contribute $363 million annually to fund these mechanisms, proportional to their GDP. Implementing such schemes offers a high return on investment, potentially yielding 11 to 28 times the cost in healthcare savings over thirty years. The piece emphasizes that high-income countries must lead this effort, as AMR is a shared global challenge requiring coordinated economic reform to prevent a post-antibiotic era.